A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.
A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85724, United States
Sacramento, California 95817, United States
Palm Beach Gardens, Florida 33418, United States
Tampa, Florida 33613, United States
Saint Lous, Missouri 63108, United States
New Hyde Park, New York 11040, United States
Rochester, New York 14620, United States
Dallas, Texas 75390, United States
Milwaukee, Wisconsin 53226, United States